MARKET

JSPR

JSPR

Jasper Therapeutics Inc
NASDAQ
1.770
-0.070
-3.80%
After Hours: 1.800 +0.03 +1.69% 19:11 12/12 EST
OPEN
1.830
PREV CLOSE
1.840
HIGH
1.890
LOW
1.770
VOLUME
574.80K
TURNOVER
--
52 WEEK HIGH
23.37
52 WEEK LOW
1.390
MARKET CAP
49.53M
P/E (TTM)
-0.2998
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at JSPR last week (1201-1205)?
Weekly Report · 5d ago
3 Penny Stocks to Watch Now, 12/4/25
TipRanks · 12/04 16:57
RBC Capital Sticks to Its Hold Rating for Jasper Therapeutics (JSPR)
TipRanks · 12/03 12:17
Positive Outlook for Jasper Therapeutics: Buy Rating Reinforced by Briquilimab’s Promising Data and Strategic Plans
TipRanks · 12/03 11:58
Analysts Have Conflicting Sentiments on These Healthcare Companies: Jasper Therapeutics (JSPR) and Azitra Inc (AZTR)
TipRanks · 12/02 20:10
Analysts Conflicted on These Healthcare Names: Jasper Therapeutics (JSPR) and Azitra Inc (AZTR)
TipRanks · 12/02 20:00
Jasper Therapeutics: Strategic Patient Selection and Consistent Drug Performance Justify Buy Rating
TipRanks · 12/02 18:15
Jasper Stock Jumps After Promising New Asthma Study Results
Benzinga · 12/02 16:14
More
About JSPR
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics targeting mast cell-driven diseases, such as Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU), and Asthma. The Company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (c-Kit) receptor on mast and stem cells. Briquilimab is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the cell-surface receptor c-Kit, also known as CD117, thereby inhibiting signaling through the receptor. The SCF/c-Kit pathway is a survival signal for mast cells. It is also developing briquilimab as a one-time conditioning therapy for severe combined immunodeficiency (SCID) patients undergoing a second stem cell transplant for which it is conducting a Phase 1/2 clinical trial.

Webull offers Jasper Therapeutics Inc stock information, including NASDAQ: JSPR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, JSPR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading JSPR stock methods without spending real money on the virtual paper trading platform.